Tianjin University of Traditional Chinese Medicine, No. 10, Poyang Lake Road, West Zone, Tuanbo New City, Jinghai District, Tianjin, China.
Tianjin University of Traditional Chinese Medicine, No. 10, Poyang Lake Road, West Zone, Tuanbo New City, Jinghai District, Tianjin, China.
Clin Chim Acta. 2019 Oct;497:95-103. doi: 10.1016/j.cca.2019.07.017. Epub 2019 Jul 17.
Coronary heart disease (CHD) is the leading cause of death worldwide, and its pathogenesis has attracted much attention. Metabolomics serves as an important tool for diagnosing diseases and exploring their pathogenesis in recent years. In this study, CHD patients were studied by comparing them with normal subjects to elucidate biomarkers that are linearly correlated with the severity of coronary stenosis.
An ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) was used to analyze the urine metabolites of CHD patients and normal subjects. A total of 131 subjects included 27 patients who presented with 50-69% coronary stenosis, 22 with 70-89% stenosis, 29 with 90-99% stenosis, 24 with 100% stenosis, and 29 normal subjects.
A total of 14 potential biomarkers associated with CHD were identified, and among them 4 biomarkers were linearly correlated with the severity of coronary stenosis in CHD patients. The metabolic pathways involved were amino acid metabolism, fatty acid metabolism, energy metabolism, and other pathways.
This study identified the biomarkers and metabolic pathways that may be involved in the occurrence and development of CHD, laying a theoretical foundation for better diagnosis and treatment of CHD in the future.
冠心病(CHD)是全球范围内的主要死亡原因,其发病机制引起了广泛关注。代谢组学近年来作为一种重要的疾病诊断和发病机制探索工具。本研究通过比较 CHD 患者与正常对照,旨在阐明与冠状动脉狭窄严重程度呈线性相关的生物标志物。
采用超高效液相色谱-四极杆飞行时间质谱联用(UPLC-Q-TOF/MS)分析 CHD 患者和正常对照的尿液代谢物。共纳入 131 例受试者,其中 27 例为狭窄程度 50%-69%的患者,22 例为狭窄程度 70%-89%的患者,29 例为狭窄程度 90%-99%的患者,24 例为狭窄程度 100%的患者,29 例为正常对照。
共鉴定出 14 个与 CHD 相关的潜在生物标志物,其中 4 个生物标志物与 CHD 患者冠状动脉狭窄的严重程度呈线性相关。涉及的代谢途径包括氨基酸代谢、脂肪酸代谢、能量代谢和其他途径。
本研究鉴定出可能参与 CHD 发生发展的生物标志物和代谢途径,为未来更好地诊断和治疗 CHD 奠定了理论基础。